If you have an Aetna plan and your gastroenterologist has prescribed Omvoh for ulcerative colitis, the short answer is that Aetna does cover it, but only after prior authorization and a substantial round of step therapy. Aetna, a CVS Health company, runs its pharmacy benefit through CVS Caremark and dispenses specialty biologics through CVS Specialty, and it documents exactly what it expects to see in a Clinical Policy Bulletin. Knowing what that bulletin asks for before your request goes in is the difference between a smooth approval and weeks of back-and-forth. This article walks through how Aetna handles Omvoh, the specific criteria it typically applies, and what to do if you receive a denial.
What Omvoh Is and Why It Needs Prior Authorization
Omvoh is the brand name for mirikizumab-mrkz, a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23, a cytokine that drives intestinal inflammation. The FDA approved it for the treatment of moderately to severely active ulcerative colitis in adults, with an initial U.S. approval in 2023. Treatment begins with an intravenous induction phase, 300 mg infused over at least 30 minutes at weeks 0, 4, and 8, followed by 200 mg given subcutaneously at week 12 and every 4 weeks thereafter. Because it is a high-cost specialty biologic, insurers including Aetna place it behind prior authorization rather than covering it automatically. The approval rested on the LUCENT program, two phase 3 trials in which 24.2% of mirikizumab patients reached clinical remission at week 12 versus 13.3% on placebo, and 49.9% reached remission at week 40 versus 25.1%.
How Aetna Coverage Works for a Specialty Biologic
Aetna documents its coverage rules for mirikizumab in Clinical Policy Bulletin 1048, which spells out the medical-necessity criteria a request must meet. Whether Omvoh is billed under your medical benefit or your pharmacy benefit depends on how and where it is administered, since the intravenous induction often runs through the medical side while subcutaneous maintenance typically moves to the pharmacy benefit managed by CVS Caremark. Either way, precertification is required, and the specialty drug is usually dispensed through CVS Specialty. Your prescriber or the specialty pharmacy submits the authorization request with your clinical documentation. The single most useful thing you can do is confirm where Omvoh sits on your own plan by using Aetna's medication search tool, which shows whether a drug is covered and at what cost once you select your specific pharmacy plan.
The Step Therapy Aetna Typically Requires
This is where Omvoh requests most often stall. Aetna's bulletin reflects a position that there is a lack of reliable evidence that Omvoh is superior to lower-cost targeted immune modulators, so it asks patients to step through several of those agents first. Under the criteria in CPB 1048, Aetna typically requires documentation of a contraindication, intolerance, or inadequate response (a one-month trial each) to a defined list of alternative targeted immune modulators before it will approve Omvoh for ulcerative colitis. That list has commonly included agents such as Entyvio, Skyrizi, Stelara, Tremfya, and an infliximab product such as Avsola, Inflectra, or Renflexis.
A few points are worth keeping in mind:
These criteria change as formularies and preferred-product lists are updated, so confirm the current version of the bulletin.
Your specific employer or individual plan may apply its own variations on top of the standard bulletin.
Documented intolerance or contraindication can satisfy a step without a full failed trial.
Building a Request That Meets the Criteria
Because the gating factor is your treatment history, the strength of your authorization comes down to documentation. The criteria in CPB 1048 turn on showing what you have already tried and how your body responded, so your record needs dates, drug names, durations, and the reason each prior therapy was stopped. A clear chronology of each targeted immune modulator you used, the length of each trial, and whether you experienced an inadequate response or a true intolerance gives the reviewer exactly what the bulletin asks for. It also helps to capture objective markers of active disease, such as endoscopy findings, fecal calprotectin, or a documented Mayo score, since the indication is reserved for moderately to severely active ulcerative colitis. When your gastroenterologist submits a request with this history already assembled, the reviewer has fewer reasons to ask for more.
What to Do If Aetna Denies Omvoh
A denial is not the end of the road, and many initial denials are reversed on appeal once the missing documentation is supplied. Aetna gives members a formal route to file an appeal or grievance when a coverage decision goes against them. Start by reading the denial letter closely, because it states the precise reason, often a step that Aetna believes was not documented or a trial it considers too short. Work with your gastroenterologist on a medical-necessity letter that answers that exact reason, attaching the records that prove each prior trial and its outcome. If your prescriber believes the required step-through agents are inappropriate for you, that clinical rationale belongs in the appeal. You can also request a peer-to-peer review, in which your physician speaks directly with an Aetna medical reviewer, and if internal appeals are exhausted you generally have the right to an external independent review.
The Bottom Line on Aetna and Omvoh
Aetna does cover Omvoh for ulcerative colitis, but it treats the drug as a later-line option that members reach after documented trials of several preferred biologics. The mechanics are consistent: prior authorization through CVS Caremark and CVS Specialty, medical-necessity criteria set out in Clinical Policy Bulletin 1048, and step therapy through a defined list of lower-cost targeted immune modulators. Because the entire decision hinges on your treatment history, the patients who clear authorization fastest are the ones whose prior therapies, durations, and outcomes are already documented when the request is filed. Verify how Omvoh sits on your own plan, confirm the current bulletin criteria with your prescriber, and keep a complete record of every therapy you have tried, so that whether your request is approved on the first pass or needs an appeal, the evidence Aetna is looking for is ready.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.